Loading...

Resapp Health Ltd
ASX:RAP

Watchlist Manager
Resapp Health Ltd Logo
Resapp Health Ltd
ASX:RAP
Watchlist
Price: 0.205 AUD Market Closed
Updated: Dec 8, 2022

Intrinsic Value

RAP's intrinsic value estimate is unreliable because it is based only on its relative value.

The intrinsic value of one RAP stock under the Base Case scenario is 0.08 AUD. Compared to the current market price of 0.205 AUD, Resapp Health Ltd is Overvalued by 61%.

The Intrinsic Value is calculated as the average of the two valuation methods:

RAP Intrinsic Value
Base Case
0.08 AUD
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

RAP Profitability Score
Profitability Due Diligence

Resapp Health Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
22/100
Profitability
Score

Resapp Health Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

RAP Solvency Score
Solvency Due Diligence

Resapp Health Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Low Altman Z-Score
Short-Term Liabilities
Long-Term Liabilities
Low D/E
47/100
Solvency
Score

Resapp Health Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
0%
Gross Margin
-276%
Operating Margin
-282%
Net Margin
-166%
FCF Margin
-171%
ROE
-317%
ROIC
Other

RAP Capital Structure
Resapp Health Ltd

Market Capitalization 176M AUD
Total Debt 0 AUD
Minority Interest 0 AUD
Preferred Equity 0 AUD
Cash and Equivalents 2.3M AUD
Short-Term Investments 110k AUD
Enterprise Value 174M AUD

Wall St
Price Targets

RAP Price Targets Summary
Resapp Health Ltd

Wall Street analysts forecast RAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RAP is 0.24 AUD .

Lowest
Price Target
Not Available
Average
Price Target
0.24 AUD
17% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

RAP Competitors
Resapp Health Ltd

RAP Suppliers & Customers
Resapp Health Ltd

Resapp Health Ltd has 5 key suppliers from 2 countries and 4 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Pharmaceuticals industry.

Resapp Health Ltd has 3 key customers from 2 countries and 2 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Pharmaceuticals industry.

Shareholder Return

RAP Price
Resapp Health Ltd

1M 1M
-
6M 6M
+86%
1Y 1Y
+260%
3Y 3Y
-23%
5Y 5Y
+177%
Annual Price Range
0.205
52w Low
0.051
52w High
0.21
Price Metrics
Average Annual Return 23.48%
Standard Deviation of Annual Returns 73.43%
Max Drawdown -90%
Shares Statistics
Market Capitalization 176M AUD
Shares Outstanding 859 697 077
Percentage of Shares Shorted
N/A

Company Profile

Resapp Health Ltd

Country

Australia

Industry

Health Care

Market Cap

176M AUD

Dividend Yield

0%

Description

ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.

Contact

QUEENSLAND
Brisbane
Level 12, 100 Creek St
+61737240035.0
https://www.resapphealth.com.au/

IPO

2005-01-12

Employees

-

Officers

CEO, MD & Director
Dr. Anthony Keating
Exec. Director of Corp. Affairs & Exec. Director
Mr. Brian Leedman B.Econ., BECON, M.B.A.
VP of Fin.
Al Rey Lunar CPA
VP of Technology & Product
Mr. Scott Savage
Company Sec.
Ms. Nicki Farley
Founder and Director of R&D of Cavidi AB
Dr. Clas Källander
Show More
VP of Commercial
Mr. Mike Connell
Scientific Advisor
Dr. Paul Porter MBBS FRACP
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one RAP stock?

The intrinsic value of one RAP stock under the Base Case scenario is 0.08 AUD.

Is RAP stock undervalued or overvalued?

Compared to the current market price of 0.205 AUD, Resapp Health Ltd is Overvalued by 61%.